Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing pharmaceutical products with a primary emphasis on rare diseases and conditions with unmet medical needs. Headquartered in Parsippany, New Jersey, Eton seeks to address gaps in patient care by offering innovative formulations of existing therapies as well as by in‐licensing or acquiring therapies that can benefit from improved delivery or broader commercial reach.
The company’s portfolio includes several FDA‐approved products. Quillivant XR®, an extended-release liquid formulation of methylphenidate for the treatment of attention‐deficit/hyperactivity disorder (ADHD), offers an alternative for patients who have difficulty swallowing tablets. Otrexup®, a single‐use, subcutaneous autoinjector delivering methotrexate, is designed for patients requiring a more convenient and reliable administration of the drug for autoimmune disorders. Triferic® (ferric pyrophosphate citrate) is indicated to maintain hemoglobin in hemodialysis patients with chronic kidney disease, offering an innovative dialysate delivery system for iron replacement therapy.
Since its founding in 2011, Eton has grown through strategic acquisitions and partnerships, expanding its commercial footprint across the United States. The company works closely with specialty pharmacies, distributors and hospital networks to ensure timely access to its therapies. Eton also evaluates international opportunities, particularly in regions where regulatory pathways align with its development objectives and where unmet needs exist for its niche treatments.
Leadership at Eton Pharmaceuticals brings extensive experience in specialty pharma commercialization and regulatory affairs. Under the guidance of President and CEO Thomas W. Carson, the team continues to pursue both in‐house development programs and external licensing agreements. Eton’s management emphasizes disciplined operational execution while maintaining a patient-centric approach to delivering therapies for underserved populations.
AI Generated. May Contain Errors.
